Calm, ground-based protein crystal growth for Indian biologics teams
TL;DR Crystwell is a contract lab that grows protein crystals and crystalline drug suspensions under the calm conditions that make microgravity useful, but on the ground. Biologics developers and structural biology groups pay per project. Orbital flights are bought from foreign providers only when ground methods fail.
Good crystals decide two things - whether a team can solve a protein's structure, and whether a high-dose antibody can be given as a small injection instead of a drip. On Earth, gravity stirs the liquid around a growing crystal and lets it sink, which tends to give uneven sizes. When a large drugmaker grew pembrolizumab crystals on the space station, flight samples came out as one population of about 39 µm, while ground controls split into 13 µm and 102 µm particles[1].
Indian groups have a domestic X-ray beamline for crystal work at RRCAT in Indore[2], but no domestic way to fly samples and get them back. A 2015 review notes researchers often waited a year or more for a flight, with heavy paperwork[3]. That's a long wait for one experiment.
What it does, in regulatory terms: a research and development lab service only. Crystwell makes no drug or clinical claims, and the client keeps its own drug-regulator duties for anything it later makes.
The seed imagined an Indian platform for crystallising proteins in orbit. I reframed it. India has no service that returns samples from orbit, and ISRO's POEM platform flies payloads that burn up with the rocket stage[4]. The more useful lesson from that drugmaker is that it took what it learned in orbit and rebuilt the effect on the ground with rotating mixers[5].
So Crystwell starts there. It runs crystallisation in gels, narrow capillaries and slowly rotating vessels, which cut the stirring and settling that gravity causes. It measures size spread and suspension viscosity for each run and hands over a recipe the client can repeat. For the rare protein that still fails, it scopes and books a flight through a foreign provider and runs matched ground controls.
There are two buyers. Formulation teams at Indian biologics and biosimilar makers want uniform crystalline suspensions for high-concentration doses. Structural biology groups at institutes and drug-discovery companies want crystals good enough to solve. I couldn't find a public price list for this kind of contract work, so expect project fees set after a feasibility run, and confirm them in interviews.
ISRO's POEM-4 flight in December 2024 carried 24 payloads, 10 of them from private entities, including biology experiments in microgravity[4]. That gives Indian teams a cheap orbital test slot for the first time, even without sample return. The 2023 space policy also set up IN-SPACe as a single window for private space activity[6].
There's no public figure for India's protein crystallisation services market, and I didn't find one for microgravity drug research either. The firmest signal is the user base - a dedicated crystallography beamline at RRCAT open to outside groups[2]. Adjacent: a US in-orbit manufacturing startup now sells in-orbit crystal work to drug makers[7], which shows buyers exist abroad. Treat both as context, not your market.
No Indian company offers this, as far as I could find. That US startup processes materials in orbit and brings them back, with a biopharma offer built on crystal forms[7]. The space station's US National Laboratory brokers pharma experiments such as that one[5]. Indian contract research firms do crystallography, but none I found sells low-convection growth as a service. The gap is a local lab that tries the cheap ground route first.
| Difficulty | Moderate (48/100) |
| Starting capital | ₹1.5–3 Cr |
| Time to launch | 9–15 months |
The lab methods are known. Proof is the hard bit. You need case studies where your recipe beat a client's own method, and drug makers are slow to share material or results. Booking a foreign flight also means export paperwork, long waits and a client who may lose patience.
The ground lab needs no special licence. The rules come in when samples fly or leave the country.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't trust AI to claim a recipe will work for a drug product. Crystal behaviour varies a lot by protein, and only real lab results count.
Want to work out the AI layer for Crystwell? Talk to Yash →
I like that this one keeps its feet on the ground, literally. It's a good fit for a protein scientist who has run crystallisation screens and can sell to formulation heads. If you want to build spacecraft then look elsewhere, because the money is in the ground work. First prove that your ground method narrows particle size for two client proteins where their in-house runs did not.
Plan for about ₹1.5–3 Cr for lab equipment, measurement tools and a small team of protein scientists.
Not for the ground lab beyond normal company registration and lab safety. Flights need IN-SPACe checks and possibly export permits for biological material.
Yes, the ground methods work anywhere, and countries with easy access to orbital flights make the flight option simpler. Check local rules on shipping biological samples.
The free Crystwell validation kit has the line-by-line capital breakdown, the effort scoring, the regulatory checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for formulation and structural biology teams, and 5 assumptions to test. Download the kit →
Thinking about building Crystwell or something close to it? The make-or-break work is landing the first two client proteins and turning those results into a case study you're allowed to show, and I can help you plan that and the raise. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.